Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 3051 - 3059 of 3059 in total
Experimental
Matched Name: … 6,11-DIHYDRO-11-ETHYL-6-METHYL-9-NITRO-5H-PYRIDO[2,3-B][1,5]BENZODIAZEPIN-5-ONE …
Matched Iupac: … 2-ethyl-10-methyl-14-nitro-2,4,10-triazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13-hexaen- …
Experimental
Matched Name: … 3,4-Dihydroxy-5-(4-oxo-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-7-yl)-2-pyrrolidinyl]methyl dihydrogen phosphate
Matched Iupac: … acid ... [(2R,3R,4S,5S)-3,4-dihydroxy-5-{4-oxo-1H,4H,5H-pyrrolo[3,2-d]pyrimidin-7-yl}pyrrolidin-2-yl]methoxy}phosphonic
Experimental
Matched Name: … (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE …
Experimental
Matched Name: … 6,7-di(sulfanyl-κS)-3,5,5a,8,9a,10-hexahydro-4H-pyrano[3,2-g]pteridin-8-yl]methyl dihydrogenato(2-) phosphate
Matched Iupac: … acid ... 2,4,6,9-tetraaza-13-molybdatetracyclo[8.7.0.0^{3,8}.0^{11,15}]heptadeca-3(8),4,11(15)-trien-16-yl]methoxy}phosphonic
Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss. It has a significant impact on both the physical and social functioning of affected individuals.[A220318,L16408] Betahistine is a histamine-like antivertigo drug used for treating symptoms associated with Ménière's disease. It is thought to...
Approved
Investigational
Matched Description: … Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing ... It has a significant impact on both the physical and social functioning of affected individuals. …
Matched Salts name: … Betahistine hydrochloride
Matched Products: … BETAHISTINE HYDROCHLORIDE
Experimental
Matched Name: … dioxo-2-(pyridin-3-ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinolin-8-yl sulfamate
Matched Iupac: … 2-[(pyridin-3-yl)methyl]-1H,2H,3H,4H,4aH,4bH,5H,6H,10bH,11H,12H,12aH-naphtho[2,1-f]isoquinolin-8-yl sulfamate
Experimental
Matched Name: … 1,3-bis-([[3-(4-{3-[3-nitro-5-(galactopyranosyloxy)-benzoylamino]-propyl}-piperazin-1-yl)-propylamino …
Matched Iupac: … -5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzene-1-carboximidic acid ... (Z)-N-{3-[4-(3-{[2-({2-[(E)-[(2-amino-3-{[(E)-{2-[(2-{[3-(4-{3-[(Z)-[hydroxy(3-nitro-5-{[(2R,3R,4S,5R ... hydroxy)methylidene]amino]ethyl}amino)-3,4-dioxocyclobut-1-en-1-yl]amino}propyl)piperazin-1-yl]propyl}-3-nitro
Experimental
Matched Name: … 1,3-bis-([3-[3-[3-(4-{3-[3-nitro-5-(galactopyranosyloxy)-benzoylamino]-propyl}-piperazin-1-yl)-propylamino …
Matched Iupac: … -5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzene-1-carboximidic acid ... (Z)-N-[3-(4-{3-[(2-{14-[(E)-[(2-amino-3-{[(E)-{3-[2-(2-{3-[(2-{[3-(4-{3-[(Z)-[hydroxy(3-nitro-5-{[(2R ... 5,8,11-trioxa-1-azatetradecan-1-yl}-3,4-dioxocyclobut-1-en-1-yl)amino]propyl}piperazin-1-yl)propyl]-3-nitro
Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918]...
Approved
Matched Description: … It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated ... [L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no ... choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and
Matched Products: … Levetiracetam in Sodium Chloride …
Displaying drugs 3051 - 3059 of 3059 in total